‘Very Small Company’ lol24 Sep 2025 11:07
Raised £50 million to date on products. AIHL projected to save NHS £13m/yr, RNR1 £330M/yr, CO2C19 is £660m/yr….think again have you done your research!
The Company has developed two CE-IVD certified products addressing unmet clinical needs in neonatology, neurology and cardiology:
1. MT-RNR1 for the avoidance of antibiotic induced hearing loss ("AIHL") in neonates; and
2. CYP2C19 for identifying stroke and cardiovascular patients unlikely to respond to medication.
Both tests have been co-developed with NHS partners and are either first-to-market or best-in-class and both tests have been recommended by NICE for NHS use in certain disease areas. In addition, both tests are backed by clear national and international clinical guidance and recommendations, with significant patient outcome impact and strong health economic and productivity gain drivers for healthcare systems.
Early national and international commercial traction is evidencing product-market fit and implementation into routine clinical use and practice in early adopter hospitals and trusts. The Company estimates that the serviceable value opportunity of both tests is more than £200 million per annum. Each country being targeted typically requires market access and reimbursement mapping, key opinion leader identification and in-country pilot implementations prior to widespread adoption for clinical use.
Availability of an individual's genetic information has a range of benefits including helping address ineffective medication and associated adverse events and can help better inform medicine selection and dosing, ultimately improving patient outcomes and reducing healthcare costs. It is estimated that the cost to the NHS of adverse drug reactions ("ADRs") is £2.2 billion per annum with ADRs accounting for 16.5% of hospital admissions. The annual costs of prescriptions to NHS England in 2023/2024 was £20 billion. Pharmacogenetics can transform the prescription of drugs, improving patient outcomes and ultimately save money for healthcare systems.
Sign In
Follow the stocks
